Nucleoside transport and its significance for anticancer drug resistance

Drug Resistance Updates

Volumn 1, Issue 5, 1998, Pages 310-324

  Mackey, John R ^a   Baldwin, Stephen A ^b   Young, James D ^a   Cass, Carol E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000398353     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(98)80047-2     Document Type: Review

References (127)

1. Griffiths M., Beaumont N., Yao S.Y., et al. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nature Med 3 1 (1997) 89-93
2. +-nucleoside cotransporter (hCNTI). Am J Physiol 272 2 41-2 (1997) C707-C714
3. Crawford C.R., Patel D.H., Naeve C., and Belt J.A. Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line. J Biol Chem 273 9 (1998) 5288-5293
4. (Pt 3). Griffiths M., Yao S., Abidi F., et al. Molecular cloning and characterization of anitrobenzylthioinosine- insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochem J 328 (1997) 739-743
5. +-dependent purine nucleoside transporter from human kidney: cloning and functional characterization. Am J Physiol 273 42 (1997) F1058-F1065
6. +/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Mol Membr Biol (1998)
7. Cass C.E. Nucleoside transport. In: Georgopapadakou N.H. (Ed). Drug Transport in Antimicrobial Therapy and Anticancer Therapy (1995), Marcel Dekker, New York 403-451
8. Griffith D.A., and Jarvis S.M. Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta Rev Biomembr 1286 3 (1996) 153-181
9. Buolamwini J.K. Nucleoside transport inhibitors: structure-activity relationships and potential therapeutic applications. Curr Med Chem 4 1 (1997) 35-66
10. Wang J., Schaner M.E., Thomassen S., Su S.F., Piquette-Miller M., and Giacomini K.M. Functional and molecular characteristics of Na(+)-dependent nucleoside transporters. Pharm Res 14 11 (1997) 1524-1532
11. Che M., Gatmaitan Z., and Arias I.M. Ectonucleotidases, purine nucleoside transporter, and function of the bile canalicular plasma membrane of the hepatocyte. FASEB J 11 2 (1997) 101-108
12. Thorn J.A., and Jarvis S.M. Adenosine transporters. Gen Pharmacol 27 4 (1996) 613-620
13. Yao S.Y., Ng A.M., Muzyka W.R., et al. Molecular cloning and functional characterization of nitrobenzylthioinosine (NBMPR)-sensitive (es) and NBMPR-insensitive (ei) equilibrative nucleoside transporter proteins (rENT1 and rENT2) from rat tissues. J Biol Chem 272 45 (1997) 28423-28430
14. Yao S.Y., Ng A.M., Ritzel M.W., Cass C.E., and Young J.D. Transport of adenosine by recombinant purine- and pyrimidine-selective sodium/nucleoside cotransporters from rat jejunum expressed in Xenopus laevis oocytes. Mol Pharm 50 6 (1996) 1529-1535
15. +-nucleoside cotransporter. J Biol Chem 270 23 (1995) 13596-13599
16. Huang Q.Q., Yao S.Y., Ritzel M.W., et al. Cloning and functional expression of a complementary DNA encoding a mammalian nucleoside transport protein. J Biol Chem 269 27 (1994) 17757-17760
17. Kwong F.Y., Wu J.S., Shi M.M., et al. Enzymic cleavage as a probe of the molecular structures of mammalian equilibrative nucleoside transporters. J Biol Chem 268 29 (1993) 22127-22134
18. Coe I.R., Griffiths M., Young J.D., Baldwin S.A., and Cass C.E. Assignment of the human equilibrative nucleoside transporter (hENT1) to 6p21.1-p21.2. Genomics 45 2 (1997) 459-460
19. Sundaram M., Yao S., Cass C.E., Baldwin S.A., and Young J.D. Chimaeric constructs between human and rat equilibrative nucleoside transporters (hENT1 and rENT1) reveal hENT1 structural domains interacting with coronary vasoactive drugs. J Biol Chem 273 (1998) 21519-21525
20. Boleti H., Coe I.R., Baldwin S.A., Young J.D., and Cass C.E. Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562). Neuropharm 36 9 (1997) 1167-1179
21. Vijayalakshmi D., and Belt J.A. Sodium-dependent nucleoside transport in mouse intestinal epithelial cells. Two transport systems with differing substrate specificities. J Biol Chem 263 36 (1988) 19419-19423
22. Huang Q.Q., Harvey C.M., Paterson A.R., Cass C.E., and Young J.D. Functional expression of Na(+)-dependent nucleoside transport systems of rat intestine in isolated oocytes of Xenopus laevis. Demonstration that rat jejunum expresses the purine-selective system N1 (cif) and a second, novel system N3 having broad specificity for purine and pyrimidine nucleosides. J Biol Chem 268 27 (1993) 20613-20619
23. +-dependent (cif) nucleoside transport in acute promyelocytic leukemia NB4 cells. J Cell Physiol 166 3 (1996) 593-600
24. Belt J.A., Harper E.H., Byl J.A., and Noel L.D. Sodium-dependent nucleoside transport inhuman myeloid leukemic cell lines and freshly isolated myeloblasts. Proc Annu Meet Am Assoc Canc Res 33 (1992) 20
25. Belt J.A., Marina N.M., Phelps D.A., and Crawford C.R. Nucleoside transport in normal and neoplastic cells. Adv Enzyme Regul 33 (1993) 235-252
26. +-dependent, guanosine-specific, nitrobenzylthioinosine-sensitive transporter in acute promyelocytic leukemia cells. J Biol Chem 272 29 (1997) 18026-18032
27. Paterson A.R., Gati W.P., Vijayalakshmi D., et al. Inhibitor-sensitive, sodium-linked transport of nucleoside analogs in leukemia cells from patients. Proc Annu Meet Am Assoc Cancer Res 34 (1993) A84
28. Cheson B.D. Miscellaneous chemotherapeutic agents. In: Devita V.T. (Ed). Cancer: Principles and Practice of Oncology. 5th edn. vol 1 (1997), Lippincott-Raven, Philadelphia 490-498
29. Aronow B., and Ullman B. Thymidine incorporation in nucleoside transport-deficient lymphoma cells. J Biol Chem 260 30 (1985) 16274-16278
30. Cass C.E., Kolassa N., Uehara Y., Dahlig-Harley E., Harley E.R., and Paterson A.R. Absence of binding sites for the transport inhibitor nitrobenzylthioinosine on nucleoside transport-deficient mouse lymphoma cells. Biochim Biophys Acta 649 3 (1981) 769-777
31. Cohen A., Ullman B., and Martin Jr. D.W. Characterization of a mutant mouse lymphoma cell with deficient transport of purine and pyrimidine nucleosides. J Biol Chem 254 1 (1979) 112-116
32. Mackey J.R., Mani R.S., Selner M., et al. Functional nucleoside transporters are required for gemcitabine influx and cytotoxicity in cancer cell lines. Cancer Res 58 (1998) 4349-4357
33. Ullman B., Coons T., Rockwell S., and McCartan K. Genetic analysis of 2′,3′-dideoxycytidine incorporation into cultured human T lymphoblasts. J Biol Chem 263 25 (1988) 12391-12396
34. Ullman B. Dideoxycytidine metabolism in wild type and mutant CEM cells deficient in nucleoside transport or deoxycytidine kinase. Adv Exp Med Biol 253B (1989) 415-420
35. Hoffman J. Murine erythroleukemia cells resistant to periodate-oxidized adenosine have lowered levels of nucleoside transporter. Adv Exp Med Biol 309A (1991) 443-446
36. Sobrero A.F., Handschumacher R.E., and Bertino J.R. Highly selective drug combinations for human colon cancer cells resistant in vitro to 5-fluoro-2′-deoxyuridine. Cancer Res 45 7 (1985) 3161-3163
37. Ellison R.R., Holland J.F., Weil M., et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 32 4 (1968) 507-523
38. Allegra C.J., and Grem J.L. Antimetabolites. In: Devita V.T. (Ed). Cancer: Principles and Practice of Oncology. 5th edn. vol 1 (1997), Lippincott-Raven, Philadelphia 490-498
39. Kufe D., Spriggs D., Egan E.M., and Munroe D. Relationships among ara-CTP pools, formation of (ara-C)DNA, and cytotoxicity of human leukemic cells. Blood 64 (1984) 54-48
40. Zittoun R., Jean-Pierre M., Delanian S., Suberville A.-M., and Thevenin D. Prognostic value of in vitro uptake and retention of cytosine arabinoside in acute myelogenous leukemia. Semin Oncol 14 (1987) 269-275
41. Rustum Y.M., and Preisler H.D. Correlation between leukemic cell retention of I-B-D-arabinofuranosylcytosine 5′-triphosphate and response to therapy. Cancer Res 39 (1979) 42-49
42. White J.C., Rathmell J.P., and Capizzi R.L. Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells. J Clin Invest 79 2 (1987) 380-387
43. Jamieson G.P., Snook M.B., and Wiley J.S. Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells. Leuk Res 14 5 (1990) 475-479
44. Wiley J.S., Jones S.P., and Sawyer W.H. Cytosine arabinoside transport by human leukaemic cells. Eur J Cancer Clin Oncol 19 8 (1983) 1067-1074
45. Ho D.H.W., and Frei III E. Clinical pharmacology of I-beta-D-arabinofuranosyl cytosine. Clin Pharmacol Therapeut 12 (1971) 944-954
46. Wiley J.S., Jones S.P., Sawyer W.H., and Paterson A.R. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J Clin Invest 69 2 (1982) 479-489
47. Wiley J.S., Woodruff R.K., Jamieson G.P., Firkin F.C., and Sawyer W.H. Cytosine arabinoside in the treatment of T-cell acute lymphoblastic leukemia. Aust NZ J Med 17 4 (1987) 379-386
48. Wiley J.S., Taupin J., Jamieson G.P., Snook M., Sawyer W.H., and Finch L.R. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J Clin Invest 75 2 (1985) 632-642
49. Gati W.P., Paterson A.R., Larratt L.M., Turner A.R., and Belch A.R. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. Blood 90 1 (1997) 346-353
50. in press. Gati W.P., Paterson A., Belch A.R., et al. Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine. Leuk Lymph (1998)
51. Capizzi R.L., Yang J.L., Cheng E., et al. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. J Clin Oncol 1 12 (1983) 763-771
52. Weick J.K., Kopecky K.J., Appelbaum F.R., et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 88 8 (1996) 2841-2851
53. Bishop J.F., Matthews J.P., Young G.A., et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87 5 (1996) 1710-1717
54. Ross S.R., McTavish D., and Faulds D. Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy. Drugs 45 5 (1993) 737-759
55. Avramis V.I., and Plunkett W. Metabolism and therapeutic efficacy of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388. Cancer Res 42 (1982) 2587-2591
56. Barrueco J.R., Jacobsen D.M., Chang C.H., Brockman R.W., and Sirotnak F.M. Proposed mechanism of therapeutic selectivity for 9-beta-D-arabinofuransyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells. Cancer Res 47 (1987) 700-706
57. Sirotnak F.M., and Barrueco J.R. Membrane transport and the antineoplastic action of nucleoside analogues. Cancer Metastasis Rev 6 4 (1987) 459-480
58. Vijayalakshmi D., Dagnino L., Belt J.A., Gati W.P., Cass C.E., and Paterson A.R. L1210/B23.I cells express equilibrative, inhibitor-sensitive nucleoside transport activity and lack two parental nucleoside transport activities. J Biol Chem 267 24 (1992) 16951-16956
59. Crawford C.R., Ng C.Y., Noel L.D., and Belt J.A. Nucleoside transport in L1210 murine leukemia cells. Evidence for three transporters. J Biol Chem 265 17 (1990) 9732-9736
60. (Meeting abstract). Patel D., Crawford C., Naeve C., and Belt J. Molecular cloning and characterization of a mouse purine-selective concentrative nucleoside transporter. Proc Annu Meet Am Assoc Cancer Res 38 (1997) A405
61. Avery T.L., Rehg J.E., Lumm W.C., Harwood F.C., Santana V.M., and Blakley R.L. Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice. Cancer Res 49 18 (1989) 4972-4978
62. King K.M., and Cass C.E. Membrane transport of 2-chloro-2′-deoxyadenosine and 2-chloro-2′-arabinofluoro-2′-deoxyadenosine is required for cytotoxicity. Proc Annu Meet Am Assoc Cancer Res 35 (1994) A3436
63. Heinemann V., Xu Y.Z., Chubb S., et al. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 52 3 (1992) 533-539
64. Baker C.H., Banzon J., Bollinger J.M., et al. 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′, 2′-difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 34 6 (1991) 1879-1884
65. Heinemann V., Hertel L.W., Grindey G.B., and Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 48 14 (1988) 4024-4031
66. Remick S.C., Grem J.L., Fischer P.H., et al. Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion. Cancer Res 50 9 (1990) 2667-2672
67. Bailey H., Wilding G., Tutsch K.D., et al. A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions. Cancer Chemother Pharmacol 30 4 (1992) 297-302
68. Fischer P.R., Willson J.K.V., Risueno C., et al. Biochemical assessment of the effects of acivicin and dipyridamole given as a continuous 72-hour intravenous infusion. Cancer Res 48 (1988) 5991-5996
69. Willson J.K.V., Fischer P.H., Tutsch K., et al. Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage. Cancer Res 48 (1988) 5585-5590
70. Willson J.K.V., Fisher P.H., Remick S.C., et al. Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans. Cancer Res 49 (1989) 1866-1870
71. Higano C.S., and Livingston R.B. Oral dipyridamole and methotrexate in human solid tumors: a toxicity trial. Cancer Chemother Pharmacol 23 4 (1989) 259-262
72. Casper E.S., Baselga J., Smart T.B., Magill G.B., Markman M., and Ranhosky A. A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 28 1 (1991) 51-54
73. Markman M., Chan T.C., Cleary S., and Howell S.B. Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole. Cancer Chemother Pharmacol 19 1 (1987) 80-83
74. Szebeni J., and Weinstein J.N. Dipyridamole binding to proteins in human plasma and tissue culture media. J Lab Clin Med 117 6 (1991) 485-492
75. Curtin N.J., Newell D.R., and Harris A.L. Modulation of dipyridamole action by alpha I acid glycoprotein. Reduced potentiation of quinazoline antifolate (CB3717) cytotoxicity by dipyridamole. Biochem Pharmacol 38 19 (1989) 3281-3288
76. Andersen K., Dellborg M., and Swedberg K. Nucleoside transport inhibition by draflazine in unstable coronary disease. Eur J Clin Pharm 51 1 (1996) 7-13
77. Lynch T.P., Jakobs E.S., Paran J.H., and Paterson A.R. Treatment of mouse neoplasms with high doses of tubercidin. Cancer Res 41 8 (1981) 3200-3204
78. Paterson A.R., Paran J.H., Yang S., and Lynch T.P. Protection of mice against lethal dosages of nebularine by nitrobenzylthioinosine, an inhibitor of nucleoside transport. Cancer Res 39 9 (1979) 3607-3611
79. Lynch T.P., Paran J.H., and Paterson A.R. Therapy of mouse leukemia L1210 with combinations of nebularine and nitrobenzylthioinosine 5′-monophosphate. Cancer Res 41 2 (1981) 560-565
80. Adjei A.A., Dagnino L., Wong M.M., and Paterson A.R. Protection against fludarabine neurotoxicity in leukemic mice by the nucleoside transport inhibitor nitrobenzylthioinosine. Cancer Chemother Pharmacol 31 1 (1992) 71-75
81. Jansen W.J., Pinedo H.M., van der Wilt C.L., Feller N., Bamberger U., and Boven E. The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumor xenografts. Eur J Cancer 31A 13-14 (1995) 2313-2319
82. Goh L.B., Mack P., and Lee C.W. Nitrobenzylthioinosine-binding protein overexpression in human breast, liver, stomach and colorectal tumour tissues. Anticancer Res 15 6B (1995) 2575-2579
83. Smith C.L., Pilarski L.M., Egerton M.L., and Wiley J.S. Nucleoside transport and proliferative rate in human thymocytes and lymphocytes. Blood 74 6 (1989) 2038-2042
84. Wiley J.S., Snook M.B., and Jamieson G.P. Nucleoside transport in acute leukaemia and lymphoma: close relation to proliferative rate. Br J Haematol 71 2 (1989) 203-207
85. Cass C.E., King K.M., Montano J.T., and Janowska-Wieczorek A. A comparison of the abilities of nitrobenzylthioinosine, dilazep, and dipyridamole to protect human hematopoietic cells from 7-deazaadenosine (tubercidin). Cancer Res 52 21 (1992) 5879-5886
86. Allay J.A., Spencer H.T., Wilkinson S.L., Belt J.A., Blakley R.L., and Sorrentino B.P. Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors. Blood 90 9 (1997) 3546-3554
87. Dagnino L., and Paterson A.R. Sodium-dependent and equilibrative nucleoside transport systems in L1210 mouse leukemia cells: effect of inhibitors of equilibrative systems on the content and retention of nucleosides. Cancer Res 50 20 (1990) 6549-6553
88. Chan T.C. Augmentation of I-beta-D-arabinofuranosylcytosine cytotoxicity in human tumor cells by inhibiting drug efflux. Cancer Res 49 10 (1989) 2656-2660
89. Santana V.M., Mirro J.J., Harwood F.C., et al. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol 9 3 (1991) 416-422
90. Alessi-Severini S., Gati W.P., Belch A.R., and Paterson A.R. Intracellular pharmacokinetics of 2-chlorodeoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia. Leukemia 9 10 (1995) 1674-1679
91. Grunewald R., Abbruzzese J.L., Tarassoff P., and Plunkett W. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27 4 (1991) 258-262
92. Petersen A.J., Brown R.D., Pope B.B., et al. Multiple myeloma: Expression of nucleoside transporters on malignant plasma cells and their relationship to cellular proliferation. Leuk Lymphoma 13 5-6 (1994) 491-499
93. Meckling-Gill K.A., Guilbert L., and Cass C.E. CSF-I stimulates nucleoside transport in S1 macrophages. J Cell Physiol 155 3 (1993) 530-538
94. Wiley J.S., Cebon J.S., Jamieson G.P., et al. Assessment of proliferative responses to granulocyte-macrophage colony-stimulating factor (GM-CSF) in acute myeloid leukaemia using a fluorescent ligand for the nucleoside transporter. Leukemia 8 1 (1994) 181-185
95. Lowenberg B., Suciu S., Archimbaud E., et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-II, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 90 8 (1997) 2952-2961
96. Wilz F., Harousseau J.L., Cahn J.Y., and Abgrall J.F. GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukemia. Blood 84 suppl 1 (1994) 231A
97. in press. Lowenberg B., Boogaerts M.A., Daenen S.M., et al. The value of different modalities of GM-CSF applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol (1998)
98. Ohno R., Naoe T., Kanamaru A., et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 83(8) (1994), Kohseisho Leukemia Study Group 2086-2092
99. Estey E., Thall P., Andreeff M., et al. Use of granulocyte colonystimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12 4 (1994) 671-678
100. Petersen A.J., Brown R.D., Gibson J., et al. Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro. Eur J Haematol 56 4 (1996) 213-220
101. Chen S.F., Cleaveland J.S., Hollmann A.B., Wiemann M.C., Parks Jr. R.E., and Stoeckler J.D. Changes in nucleoside transport of HL-60 human promyelocytic cells during N,N-dimethylformamide induced differentiation. Cancer Res 46 7 (1986) 3449-3455
102. Sokoloski J.A., Beardsley G.P., and Sartorelli A.C. Induction of HL-60 leukemia cell differentiation by tetrahydrofolate inhibitors of de novo purine nucleotide biosynthesis. Cancer Chemother Pharmacol 28 (1991) 39-44
103. Lee C.W., Sokoloski J.A., Sartorelli A.C., and Handschumacher R.E. Differentiation of HL-60 cells by dimethylsulfoxide activates a Na(+)-dependent nucleoside transport system. In Vivo 8 5 (1994) 795-801
104. (Pt 1). Lee C.W., Sokoloski J.A., Sartorelli A.C., and Handschumacher R.E. Induction of the differentiation of HL-60 cells by phorbol 12-myristate 13-acetate activates a Na(+)-dependent uridinetransport system. Involvement of protein kinase. Biochem J 274 (1991) 85-90
105. Ishii-Morita H., Agbaria R., Mullen C.A., et al. Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther 4 3 (1997) 244-251
106. Culver K., Ram Z., Wallbridge S., et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256 (1992) 1550-1553
107. Mahony W.B., Domin B.A., and Zimmerman T.P. Ganciclovir permeation of the human erythrocyte membrane. Biochem Pharmacol 41 2 (1991) 263-271
108. Morgan P.F., Fine R.L., Montgomery P., and Marangos P.J. Multidrug resistance in MCF-7 human breast cancer cells is associated with increased expression of nucleoside transporters and altered uptake of adenosine. Cancer Chemother Pharmacol 29 2 (1991) 127-132
109. Higashigawa M., Ido M., Kuwabara H., et al. Membrane transport of l-beta-D-arabinofuranosylcytosine and accumulation of l-beta-D-arabinofuranosylcytosine 5′-triphosphate in P388 murine leukemic cells resistant to vincristine. Leuk Res 15 4 (1991) 255-262
110. Bergman A.P., and Veerman G. Increased sensitivity to gemcitabine of MDR human cancer cells. Proc Annu Meet Am Assoc Cancer Res 39 (1998) 216
111. Fox M., Boyle J.M., and Kinsella A.R. Nucleoside salvage and resistance to antimetabolite anticancer agents. Br J Cancer 64 3 (1991) 428-436
112. Pickard M., and Kinsella A. Influence of both salvage and DNA damage response pathways on resistance to chemotherapeutic antimetabolites. Biochem Pharmacol 52 3 (1996) 425-431
113. Kinsella A.R., Smith D., and Pickard M. Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage. Br J Cancer 75 7 (1997) 935-945
114. Weber G. Biochemical strategy of cancer cells and the design of chemotherapy: G.H.A. Clowes Memorial Lecture. Cancer Res 43 8 (1983) 3466-3492
115. Plagemann P.G., Wohlhueter R.M., and Woffendin C. Nucleoside and nucleobase transport in animal cells. Biochim Biophys Acta 947 3 (1988) 405-443
116. Turner R.N., Aherne G.W., and Curtin N.J. Selective potentation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage. Br J Cancer 76 10 (1997) 1300-1307
117. Grem J.L. Biochemical modulation of fluorouracil by dipyridamole: preclinical and clinical experience. Semin Oncol 19 2 Suppl 3 (1992) 56-65
118. Pt 1. Grem J.L., and Fischer P.H. Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels. Cancer Res 46 12 (1986) 6191-6199
119. Collins K.D., and Stark G.R. Aspartate transcarbamylase. Interaction with the transition state analogue N-(phosphonacetyl)-L-aspartate. J Biol Chem 246 21 (1971) 6599-6605
120. Van Mouwerik T.J., Pangallo C.A., Willson J.K., and Fischer P.H. Augmentation of methotrexate cytotoxicity in human colon cancer cells achieved through inhibition of thymidine salvage by dipyridamole. Biochem Pharmacol 36 6 (1987) 809-814
121. Cabral S., Leis S., Bover L., Nembrot M., and Mordoh J. Dipyridamole inhibits reversion by thymidine of methotrexate effect and increases drug uptake in Sarcoma 180 cells. Proc Natl Acad Sci USA 81 10 (1984) 3200-3203
122. Jarvis S.M., Hammond J.R., Paterson A.R., and Clanachan A.S. Species differences in nucleoside transport. A study of uridine transport and nitrobenzylthioinosine binding by mammalian erythrocytes. Biochem J 208 1 (1982) 83-88
123. Yang J.L., White J.C., and Capizzi R.L. Modulation of the cellular pharmacokinetics of ara-CTP in human leukemic blasts by dipyridamole. Cancer Chemother Pharmacol 29 3 (1992) 236-240
124. Jamieson G.P., Snook M.B., Bradley T.R., Bertoncello I., and Wiley J.S. Transport and metabolism of l-beta-D-arabinofuranosylcytosine in human ovarian adenocarcinoma cells. Cancer Res 49 2 (1989) 309-313
125. (Pt 3). Boumah C.E., Hogue D.L., and Cass C.E. Expression of high levels of nitrobenzylthioinosine-sensitive nucleoside transport in cultured human choriocarcinoma (BeWo) cells. Biochem J 288 (1992) 987-996
126. (Pt I). Goh L.B., and Lee C.W. Reduction of equilibrative nitrobenzylthioinosine-sensitive nucleoside transporter in tamoxifen-treated MCF-7 cells: an oestrogen-reversible phenomenon. Biochem J 327 (1997) 31-36
127. Paterson A.R., Yang S.E., Lau E.Y., and Cass C.E. Low specificity of the nucleoside transport mechanism of RPMI 6410 cells. Mol Pharmacol 16 3 (1979) 900-908